17 February 2021 in Neurology
Objective To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). Methods Participants (aged 36–85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co–primary outcome measures were 6-minute walk distance (6MWD) and safety. Results Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24–104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively). Conclusion Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint. Clinical Trial Registration Clinicaltrials.gov identifier NCT02573467. Classification of Evidence This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.
6 September 2019 in Breast Cancer Research and Treatment
6 February 2013 in Neurogastroenterology & Motility
16 March 2012 in The Journal of School Nursing
This study examined the initiation and logistics, funding, perceived barriers and benefits, and disruption of school activities by school-located influenza vaccination (SLIV) programs conducted during the 2008–2009 influenza season. Seventy-two interviews using a structured protocol were conducted with 26 teachers, 16 school administrators, and 30 health care professionals from 34 schools in 8 school districts. SLIV programs used a variety of locations, scheduling and staffing options, and methods for receiving parental consent and screening children. Health care professionals were primarily responsible for implementing SLIV programs, and most administrators and health care professionals considered programs easy to initiate. Health care professionals identified successful programs as requiring adequate planning/coordination, a dedicated program coordinator, and a consistent funding source. Most respondents (96%) reported minimal school-day disruptions. The perception of most stakeholders is that SLIV programs can be relatively easy to initiate, minimally disruptive and can become more efficient with experience, especially with feedback from all stakeholders.
18 February 2015 in International Journal of Digital Curation
Partnerships between educational programs and research centers are vital to meeting the escalating workforce demands in data curation. They offer a platform for educators to increase their knowledge of current best practices and emerging challenges in the field. Student internships can be key to the success of these partnerships, not just for the students who gain authentic experience in facilities that excel at data intensive research and data services. Such partnerships provide an effective platform for rich and mutually beneficial engagement among educators, data professionals, scientists, and students. This paper reports on results from the Data Curation Education in Research Centers (DCERC) program aimed at developing a model for data curation education featuring field experiences in exemplar research centers. A strength of the DCERC model is its emphasis on facilitating mutual exchange of information among the DCERC program mentors and students. This model has evolved as a result of iterative and gradual refinements to the program model based upon information gathered from the formative evaluation. These refinements not only resulted in improved outcomes for the program participants but also, we believe, a more sustainable model for the program that leverages the knowledge base of the research scientists and students through peer-to-peer learning, rather than a traditional expert to trainee model. This paper describes formative evaluation findings that shaped the development of the DCERC program. We conclude with a discussion of the critical features of this model for the development of similar programs, and a data curation workforce that is able to accommodate and adapt to emergent data needs in a variety of environments.
13 November 2022 in Quality of Life Research